Clinical Features and Outcomes of Patients with Double-Hit/Triple-Hit Multiple Myeloma Detected at Relapse
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology
Link
https://link.springer.com/content/pdf/10.1007/s12288-022-01571-9.pdf
Reference15 articles.
1. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet 394:29–38. https://doi.org/10.1016/S0140-6736(19)31240-1
2. Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21:1630–1642. https://doi.org/10.1016/S1470-2045(20)30525-8
3. Voorhees PM, Investigators for the GT, Kaufman JL, Laubach J, Investigators for the GT, et al (2020) ;136:936–45. https://doi.org/10.1182/BLOOD.2020005288
4. Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S et al (2018) Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia 32:102–110. https://doi.org/10.1038/LEU.2017.179
5. Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H et al Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance. Scientific Reports 2020;10. https://doi.org/10.1038/S41598-020-62885-0
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3